Maze Therapeutics Inc (MAZE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 189,247 | 196,812 | 29,158 | 99,919 |
| Marketable Securities | 152,670 | N/A | N/A | N/A |
| TOTAL | $349,717 | $201,671 | $34,110 | $106,149 |
| Non-Current Assets | ||||
| PPE Net | 5,044 | 6,668 | 8,845 | 12,402 |
| Investments And Advances | 18,114 | 0 | 0 | 0 |
| Other Non-Current Assets | 24,252 | 32,203 | 28,549 | 31,406 |
| TOTAL | $47,410 | $38,871 | $37,394 | $43,808 |
| Total Assets | $397,127 | $240,542 | $71,504 | $149,957 |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 1,794 | 1,939 | 2,019 | 1,585 |
| Accrued Expenses | 15,967 | 14,102 | 9,808 | 14,874 |
| TOTAL | $22,556 | $20,673 | $16,316 | $20,783 |
| Non-Current Liabilities | ||||
| Other Non-Current Liabilities | 19,605 | 531,052 | 429,036 | 411,633 |
| TOTAL | $19,605 | $531,052 | $429,036 | $411,633 |
| Total Liabilities | $42,161 | $551,725 | $445,352 | $432,416 |
| Shareholders' Equity | ||||
| Shares Outstanding, K | 49,709 | N/A | N/A | N/A |
| Common Shares | 49 | 2 | 2 | 2 |
| Retained earnings | -489,547 | -358,427 | -395,686 | -295,271 |
| Other shareholders' equity | 110 | 0 | 0 | 0 |
| TOTAL | $354,966 | $-311,183 | $-373,848 | $-282,459 |
| Total Liabilities And Equity | $397,127 | $240,542 | $71,504 | $149,957 |